This pilot study aims to evaluate the tolerability, pharmacokinetic profile, and antitumor activity of apatinib plus gefitinib as a therapy for EGFR‐mutant advanced NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.